Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
Darnatein, a subsidiary of OSR Holdings (NASDAQ: OSRH), will present scientific data at the 14th International Bone Morphogenetic Protein (BMP) Conference from May 2-6, 2025. CEO Dr. Senyon Choe will showcase the company's proprietary platform technology and two key biologic candidates: DRT-101 for joint cartilage regeneration and DRT-102 for spinal bone repair.
The company has achieved significant milestones, including preclinical validation of both candidates demonstrating safety and enhanced tissue regeneration. Darnatein is conducting IND-enabling studies with BioToxTech and UC San Diego, working towards IND submissions to Korean MFDS and U.S. FDA for DRT-101.
Darnatein, una controllata di OSR Holdings (NASDAQ: OSRH), presenterà dati scientifici al 14° Congresso Internazionale sulle Proteine Morfogenetiche Ossee (BMP) dal 2 al 6 maggio 2025. Il CEO, Dr. Senyon Choe, illustrerà la tecnologia proprietaria della piattaforma aziendale e due importanti candidati biologici: DRT-101 per la rigenerazione della cartilagine articolare e DRT-102 per la riparazione ossea spinale.
L'azienda ha raggiunto traguardi significativi, inclusa la validazione preclinica di entrambi i candidati che dimostra sicurezza e migliorata rigenerazione dei tessuti. Darnatein sta conducendo studi per l'abilitazione IND con BioToxTech e UC San Diego, lavorando verso le sottomissioni IND al MFDS coreano e alla FDA statunitense per DRT-101.
Darnatein, una subsidiaria de OSR Holdings (NASDAQ: OSRH), presentará datos científicos en la 14ª Conferencia Internacional de Proteínas Morfogenéticas Óseas (BMP) del 2 al 6 de mayo de 2025. El CEO, Dr. Senyon Choe, mostrará la tecnología propietaria de la plataforma de la compañía y dos candidatos biológicos clave: DRT-101 para la regeneración del cartílago articular y DRT-102 para la reparación ósea espinal.
La empresa ha logrado hitos importantes, incluida la validación preclínica de ambos candidatos que demuestra seguridad y una regeneración tisular mejorada. Darnatein está realizando estudios para habilitar IND con BioToxTech y UC San Diego, trabajando para las presentaciones IND ante el MFDS coreano y la FDA de EE. UU. para DRT-101.
Darnatein은 OSR Holdings (NASDAQ: OSRH)의 자회사로서, 2025년 5월 2일부터 6일까지 개최되는 제14회 국제 골형성 단백질(BMP) 학회에서 과학적 데이터를 발표할 예정입니다. CEO인 Dr. Senyon Choe는 회사의 독자적인 플랫폼 기술과 두 가지 주요 생물학적 후보물질인 관절 연골 재생용 DRT-101과 척추 골 수복용 DRT-102를 선보일 것입니다.
회사는 두 후보물질 모두의 안전성과 조직 재생 촉진을 입증한 전임상 검증 등 중요한 이정표를 달성했습니다. Darnatein은 BioToxTech 및 UC San Diego와 함께 IND 승인 연구를 진행 중이며, DRT-101의 한국 MFDS 및 미국 FDA에 대한 IND 제출을 준비하고 있습니다.
Darnatein, une filiale de OSR Holdings (NASDAQ : OSRH), présentera des données scientifiques lors de la 14e Conférence Internationale sur les Protéines Morphogénétiques Osseuses (BMP) du 2 au 6 mai 2025. Le PDG, Dr Senyon Choe, mettra en avant la technologie propriétaire de la plateforme de l'entreprise ainsi que deux candidats biologiques clés : DRT-101 pour la régénération du cartilage articulaire et DRT-102 pour la réparation osseuse de la colonne vertébrale.
L'entreprise a franchi des étapes importantes, notamment la validation préclinique des deux candidats démontrant leur sécurité et une régénération tissulaire améliorée. Darnatein mène des études pour l'autorisation IND avec BioToxTech et l'UC San Diego, en vue des soumissions IND auprès du MFDS coréen et de la FDA américaine pour DRT-101.
Darnatein, eine Tochtergesellschaft von OSR Holdings (NASDAQ: OSRH), wird wissenschaftliche Daten auf der 14. Internationalen Konferenz für Knochenmorphogenetische Proteine (BMP) vom 2. bis 6. Mai 2025 präsentieren. CEO Dr. Senyon Choe wird die firmeneigene Plattformtechnologie sowie zwei wichtige biologische Kandidaten vorstellen: DRT-101 zur Gelenkknorpelregeneration und DRT-102 zur Wirbelsäulen-Knochenreparatur.
Das Unternehmen hat bedeutende Meilensteine erreicht, darunter die präklinische Validierung beider Kandidaten, die Sicherheit und verbesserte Geweberegeneration nachweisen. Darnatein führt IND-fördernde Studien mit BioToxTech und der UC San Diego durch und arbeitet auf IND-Anmeldungen bei der koreanischen MFDS und der US-amerikanischen FDA für DRT-101 hin.
- None.
- None.
The BMP Conference brings together leading global researchers to explore the latest breakthroughs in BMP-related biology and regenerative medicine. This year's program highlights novel technologies and fundamental research in tissue and organ regeneration. (https://www.14thbmpconference2025.com/)
Dr. Senyon "Teddy" Choe, CEO of Darnatein, will deliver a scientific presentation on May 3, titled:
"Design-Augmented Synthetic BMP Chimeras as Super-Agonists for Bone and Cartilage Regeneration."
The presentation will showcase Darnatein's proprietary platform technology that has led to the development of DRT-101 and DRT-102, two novel biologic candidates engineered to function as BMP super-agonists. DRT-101 with good preclinical safety profiles is being developed for joint cartilage regeneration, while DRT-102 is focused on spinal bone repair.
"This presentation reflects Darnatein's growing leadership in synthetic regenerative biologics," said Dr. Choe. "Our DA Biologics platform is enabling the creation of highly potent, next-generation growth factors with potential to transform musculoskeletal repair."
Darnatein's participation at the BMP Conference underscores a year of significant progress, including:
- Preclinical validation of DRT-101 and DRT-102 demonstrating safety and enhanced regeneration of cartilage and bone tissue.
- Ongoing IND-enabling studies in collaboration with BioToxTech, a publicly-listed CRO based in
South Korea and the University ofCalifornia ,San Diego , aimed at advancing DRT-101 toward IND submissions with the Korean MFDS andU.S. FDA.
The company remains committed to expanding its Design-Augmented Biologics platform to address unmet needs in regenerative medicine globally.
About Darnatein
Darnatein is a biotechnology subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH) focused on the development of design-augmented biologics for regenerative medicine. The company's proprietary platform harnesses synthetic biology and protein engineering to create next-generation growth factors for musculoskeletal and tissue repair. Lead candidates DRT-101 and DRT-102 are being developed for joint cartilage and spinal bone regeneration, respectively.
About OSR Holdings
OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. OSR aims to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Its current operating businesses (through three wholly-owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer ("Vaximm"), (ii) developing design-augmented biologics for age-related and other degenerative diseases ("Darnatein") and (iii) neurovascular intervention medical device and systems distribution in
Contact:
ir@osr-holdings.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/darnatein-to-present-at-14th-international-bmp-conference-highlighting-advances-in-regenerative-biologics-302444889.html
SOURCE OSR Holdings Inc.
FAQ
What will Darnatein (OSRH) present at the 2025 BMP Conference?
What are the main drug candidates being developed by Darnatein (OSRH)?
What is the current development stage of Darnatein's DRT-101?
Who is presenting Darnatein's research at the 2025 BMP Conference?
